

# Ian N Bruce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8639870/publications.pdf>

Version: 2024-02-01

292  
papers

32,154  
citations

12330

69  
h-index

4432

172  
g-index

300  
all docs

300  
docs citations

300  
times ranked

31709  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
2	The effects of disease activity, inflammation, depression and cognitive fatigue on resting state fMRI in systemic lupus erythematosus. Rheumatology, 2022, 61, SI39-SI47.	1.9	3
3	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology, 2022, 61, 4006-4015.	1.9	14
4	Immune gene expression and functional networks in distinct lupus nephritis classes. Lupus Science and Medicine, 2022, 9, e000615.	2.7	3
5	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
6	Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study. Clinical Immunology, 2022, 236, 108948.	3.2	4
7	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatology, The, 2022, 4, e282-e292.	3.9	34
8	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
9	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Science and Medicine, 2022, 9, e000634.	2.7	18
10	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
11	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.9	38
12	Pregnancy outcomes of a joint obstetric and rheumatology clinic in a tertiary centre: a 2-year retrospective study of 98 pregnancies. Rheumatology Advances in Practice, 2022, 6, rkac026.	0.7	2
13	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 1822-1828.	3.4	9
14	P039 – Septic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus. Rheumatology, 2022, 61, .	1.9	0
15	P240 – Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: a systematic review update. Rheumatology, 2022, 61, .	1.9	0
16	P068 – Monitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. Rheumatology, 2022, 61, .	1.9	0
17	Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. Journal of Comparative Effectiveness Research, 2022, 11, 765-777.	1.4	14
18	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases, 2022, 81, 962-969.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000584.	2.7	5
20	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. <i>Rheumatology</i> , 2021, 60, 3747-3759.	1.9	26
21	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3262-3267.	1.9	5
22	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22
23	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021, 60, 125-131.	1.9	6
24	Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Rheumatology</i> , The, 2021, 3, e101-e110.	3.9	9
25	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , 2021, 60, 1480-1490.	1.9	7
26	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE—data from the BSR audit of systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 1474-1479.	1.9	8
27	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. <i>Lupus Science and Medicine</i> , 2021, 8, e000459.	2.7	7
28	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021, 8, e000433.	2.7	7
29	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
30	The effects of disease activity on neuronal and behavioural cognitive processes in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 61, 195-204.	1.9	8
31	P169—A validated two-score system for interferon is a predictor of response to rituximab in SLE. <i>Rheumatology</i> , 2021, 60, .	1.9	0
32	P096—Pregnancy outcomes in women attending a joint obstetric and rheumatology clinic in a tertiary centre over a 2-year period. <i>Rheumatology</i> , 2021, 60, .	1.9	0
33	Evolving concepts in systemic lupus erythematosus damage assessment. <i>Nature Reviews Rheumatology</i> , 2021, 17, 307-308.	8.0	10
34	What Does it Mean to be a British Isles Lupus Assessment Group—Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. <i>Arthritis and Rheumatology</i> , 2021, 73, 2059-2068.	5.6	12
35	P166—Multimorbidity in SLE, a barrier to clinical trial eligibility: results from the BILAG-BR. <i>Rheumatology</i> , 2021, 60, .	1.9	0
36	P170—The validity and utility of the SLE-key® rule-out serological test when applied in a selected cohort of patients with SLE and other connective tissue diseases. <i>Rheumatology</i> , 2021, 60, .	1.9	0

#	ARTICLE	IF	CITATIONS
37	O17â€fEffectiveness of rituximab in the treatment of neuro-psychiatric SLE: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2021, 60, .	1.9	1
38	O19â€fEasy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. Rheumatology, 2021, 60, .	1.9	0
39	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
40	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology, 2021, 60, 5397-5407.	1.9	48
41	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
42	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 21-30.	0.1	4
43	The role of antirheumatics in patients with COVID-19. Lancet Rheumatology, The, 2021, 3, e447-e459.	3.9	36
44	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Research and Therapy, 2021, 23, 203.	3.5	3
45	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). Lupus Science and Medicine, 2021, 8, e000513.	2.7	8
46	Differential levels of IFNÎ± subtypes in autoimmunity and viral infection. Cytokine, 2021, 144, 155533.	3.2	12
47	Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EVALuation of Novel Targets in RA (PREVeNT-RA) Cohort. Arthritis Research and Therapy, 2021, 23, 210.	3.5	5
48	Association between age at disease onset of anti-neutrophil cytoplasmic antibodyâ€associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 2021, 60, 617-628.	1.9	22
49	1124â€...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
50	1107â€...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
51	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
52	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
53	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
54	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39

#	ARTICLE	IF	CITATIONS
55	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
56	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
57	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
58	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
59	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 382, 211-221.	27.0	725
60	P175â€fMASTERPLANS: prediction of response to rituximab in SLE using a validated two-score system for interferon. <i>Rheumatology</i> , 2020, 59, .	1.9	0
61	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , The, 2020, 2, e735-e736.	3.9	3
62	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. <i>RMD Open</i> , 2020, 6, e001257.	3.8	21
63	Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. <i>Lupus Science and Medicine</i> , 2020, 7, e000350.	2.7	5
64	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
65	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
66	A molecular taxonomy for systemic autoimmune rheumatic diseases (SARDs): learning lessons from oncology?. <i>Rheumatology</i> , 2020, 59, 2193-2194.	1.9	1
67	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). <i>Clinical Immunology</i> , 2020, 214, 108375.	3.2	19
68	The challenges in data integration â€“ heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus. <i>BMC Medical Research Methodology</i> , 2020, 20, 164.	3.1	9
69	Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. <i>Lancet Rheumatology</i> , The, 2020, 2, e99-e109.	3.9	38
70	Probabilistic Approaches to Overcome Content Heterogeneity in Data Integration: A Study Case in Systemic Lupus Erythematosus. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 387-391.	0.3	0
71	Antinuclear Antibodyâ€Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70
72	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	1.6	77

#	ARTICLE	IF	CITATIONS
73	008â€fSymptoms in first degree relatives of patients with rheumatoid arthritis: evaluation of data from the symptoms in persons at risk of rheumatoid arthritis questionnaire. Rheumatology, 2019, 58, .	1.9	0
74	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology, The, 2019, 1, e208-e219.	3.9	250
75	233â€fEnhancing quality improvement capacity through the British Society for Rheumatologyâ€™s multi-region audit into the management of adults with systemic lupus erythematosus. Rheumatology, 2019, 58, .	1.9	0
76	098â€fQuality improvement to halve non-adherence to methotrexate. Rheumatology, 2019, 58, .	1.9	0
77	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
78	242â€fBaseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	1.9	0
79	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Research and Therapy, 2019, 21, 147.	3.5	20
80	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factorâ€“treated rheumatoid arthritis patients. Rheumatology, 2019, 58, 2162-2169.	1.9	26
81	145â€fThe British Society for Rheumatologyâ€™s Choosing Wisely UK recommendations. Rheumatology, 2019, 58, .	1.9	0
82	A Multicenter, Randomized, Placeboâ€Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1437-1449.	5.6	77
83	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open, 2019, 9, e025687.	1.9	81
84	Clinical applications of machine learning algorithms: beyond the black box. BMJ: British Medical Journal, 2019, 364, l886.	2.3	213
85	Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Annals of the Rheumatic Diseases, 2019, 78, 934-940.	0.9	50
86	Rheumatoid arthritis reprograms circadian output pathways. Arthritis Research and Therapy, 2019, 21, 47.	3.5	29
87	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
88	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
89	FRI0188â€...EARLY RENAL IMPROVEMENTS FOLLOWING RITUXIMAB IN LUPUS NEPHRITIS. , 2019, , .		0
90	FRI0173â€...HOW WELL DO CLINICAL TRIALS REPRESENT REAL WORLD LUPUS NEPHRITIS PATIENTS?. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	199â€¦Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. , 2019, , .		2
92	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Science and Medicine, 2019, 6, e000342.	2.7	15
93	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
94	Clinical Markers, Metrics, Indices, and Clinical Trials. , 2019, , 614-630.		7
95	Current challenges in the development of new treatments for lupus. Annals of the Rheumatic Diseases, 2019, 78, 729-735.	0.9	39
96	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
97	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	2.7	62
98	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
99	Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus, 2018, 27, 681-687.	1.6	49
100	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
101	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology, 2018, 57, 14-18.	1.9	43
102	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2018, 57, 470-479.	1.9	73
103	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology, 2018, 57, e1-e45.	1.9	247
104	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	3.4	26
105	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
106	Vitamin D and systemic lupus erythematosus - The hype and the hope. Autoimmunity Reviews, 2018, 17, 19-23.	5.8	52
107	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
108	136â€¦Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. Rheumatology, 2018, 57, .	1.9	3



#	ARTICLE	IF	CITATIONS
109	126â€fCross sectional validation of BILAG2004-Pregnancy Index. Rheumatology, 2018, 57, .	1.9	0
110	Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors. Lupus Science and Medicine, 2018, 5, e000267.	2.7	19
111	Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine, 2018, 7, 356.	2.4	215
112	QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000272.	2.7	22
113	137â€fPredictors of hypogammaglobulinaemia in rituximab treated systemic lupus erythematosus and vasculitis patients. Rheumatology, 2018, 57, .	1.9	0
114	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 222-231.	13.7	396
115	Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Research and Therapy, 2018, 20, 173.	3.5	41
116	127â€fQuality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. Rheumatology, 2018, 57, .	1.9	1
117	O21â€fBILAG2004-Pregnancy index is sensitive to change. Rheumatology, 2018, 57, .	1.9	0
118	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. Rheumatology, 2018, 57, 1502-1503.	1.9	12
119	Vitamin D treatment for connective tissue diseases: hope beyond the hype?. Rheumatology, 2017, 56, 178-186.	1.9	22
120	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
121	Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease. BBA Clinical, 2017, 7, 16-22.	4.1	34
122	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	1.6	52
123	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	3.8	29
124	Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Seminars in Arthritis and Rheumatism, 2017, 47, 65-78.	3.4	8
125	Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Seminars in Arthritis and Rheumatism, 2017, 47, 384-396.	3.4	20
126	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. Lupus Science and Medicine, 2017, 4, e000173.	2.7	25



#	ARTICLE	IF	CITATIONS
127	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 2017, 56, 1041-1043.	1.9	2
128	Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 131-142.	5.6	47
129	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
130	319.â€fTHE EFFECTS OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS ON ATTENTION. Rheumatology, 2017, 56, .	1.9	0
131	Evaluation of non-contrast MRI biomarkers in lupus nephritis. Clinical and Experimental Rheumatology, 2017, 35, 954-958.	0.8	4
132	E70â€fA Stratified Medicine Approach to Drug Response in Systemic Lupus Erythematosus. Rheumatology, 2016, , .	1.9	0
133	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
134	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Science and Medicine, 2016, 3, e000143.	2.7	50
135	Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. Scientific Reports, 2016, 6, 22341.	3.3	54
136	Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus, 2016, 25, 699-709.	1.6	82
137	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 1505-1513.	3.4	45
138	Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 2929-2935.	5.6	30
139	Cardiovascular risk and its modification in patients with connective tissue diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 81-94.	3.3	12
140	A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology, 2016, 55, 382-384.	1.9	45
141	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
142	Medication-related side effects in vasculitis: a patient self-report survey of awareness and reported uptake of protective therapy. Rheumatology, 2016, 55, 185-186.	1.9	0
143	O41.â€fAnti-Citrullinated Protein Antibody Status in the General Population and as a Predictor of Future Inflammatory Polyarthritis: The Epic-2-Noar Study. Rheumatology, 2015, , .	1.9	0
144	O14.â€fVitamin D Improves Endothelial Function and Endothelial Repair in Systemic Lupus Erythematosus. Rheumatology, 2015, , .	1.9	0

#	ARTICLE	IF	CITATIONS
145	O19.â€fAcute Necrotizing Pancreatitis in SLE: A Case Report and Literature Review. Rheumatology, 2015, , .	1.9	0
146	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 2015, 74, 1882-1885.	0.9	64
147	Mapping the disease-specific LupusQoL to the SF-6D. Quality of Life Research, 2015, 24, 1749-1758.	3.1	11
148	Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus. Lupus, 2015, 24, 1239-1247.	1.6	28
149	O10.â€fRisk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	1.9	0
150	Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using 18F-fluorodeoxyglucose PET-CT and MRI: a pilot study. Lancet, The, 2015, 385, S91.	13.7	16
151	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
152	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. Arthritis Care and Research, 2015, 67, 128-135.	3.4	39
153	Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nature Reviews Rheumatology, 2015, 11, 390-400.	8.0	221
154	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology, 2015, 54, 1780-1791.	1.9	69
155	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	12.8	149
156	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
157	Indications for IVIG in rheumatic diseases. Rheumatology, 2015, 54, 383-391.	1.9	63
158	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
159	Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 2015, 24, 42-49.	1.6	106
160	Clinical features of psoriatic arthritis. , 2015, , 989-997.		1
161	Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 1144-1150.	0.9	75
162	The Effect of Type 1 IFN on Human Aortic Endothelial Cell Function <i>In Vitro</i>: Relevance to Systemic Lupus Erythematosus. Journal of Interferon and Cytokine Research, 2014, 34, 404-412.	1.2	11

#	ARTICLE	IF	CITATIONS
163	The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. <i>Lupus</i> , 2014, 23, 273-283.	1.6	23
164	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
165	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq1 1 0.784314 rgBT /Overlock 0.9 75	0.9	75
166	Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2014, 66, 1374-1379.	3.4	45
167	Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. <i>Lupus</i> , 2014, 23, 819-824.	1.6	27
168	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	2.0	28
169	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 684-690.	0.9	31
170	Improving cardiovascular outcomes in rheumatic diseases: Therapeutic potential of circulating endothelial progenitor cells. , 2014, 142, 231-243.		19
171	25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1167-1176.	3.4	49
172	The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 352-361.	3.4	118
173	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
174	Regulatory T cells in Systemic Lupus Erythematosus and Pregnancy. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 588-595.	1.2	24
175	Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2013, 65, 122-126.	3.4	19
176	Brief Report: Shortened Telomere Length in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 2013, 65, 1319-1323.	6.7	38
177	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 227-234.	2.0	91
178	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. <i>Pharmacogenomics Journal</i> , 2013, 13, 137-147.	2.0	67
179	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1517-1523.	0.9	5
180	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78

#	ARTICLE	IF	CITATIONS
181	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 1224-1231.	6.7	63
182	Cardiovascular risk and inflammatory rheumatic diseases. Clinical Medicine, 2013, 13, 395-397.	1.9	13
183	Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clinical and Experimental Rheumatology, 2013, 31, 225-33.	0.8	14
184	25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology, 2012, 51, 544-551.	1.9	77
185	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1350-1354.	0.9	39
186	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
187	Construct and Criterion Validity of the Short Form-6D Utility Measure in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 735-742.	2.0	17
188	Modifiable risk factors for RA: prevention, better than cure?. Rheumatology, 2012, 51, 499-512.	1.9	90
189	Endothelial progenitor cells: a new player in lupus?. Arthritis Research and Therapy, 2012, 14, 203.	3.5	16
190	Golimumab for the Treatment of Psoriatic Arthritis. Pharmacoeconomics, 2012, 30, 257-270.	3.3	28
191	Investigation of IL1, VEGF, PPARC and MEFV genes in psoriatic arthritis susceptibility: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 313-314.	0.9	15
192	The BILAG-2004 systems tallyâ€”a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology, 2012, 51, 2099-2105.	1.9	13
193	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2012, 51, 634-643.	1.9	102
194	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
195	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales. Clinical Rheumatology, 2012, 31, 1005-1012.	2.2	13
196	Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care and Research, 2012, 64, 132-137.	3.4	126
197	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 1726-1732.	0.9	132
198	SLE and pregnancy: the potential role for regulatory T cells. Nature Reviews Rheumatology, 2011, 7, 124-128.	8.0	32

#	ARTICLE	IF	CITATIONS
199	An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 1459-1465.	1.6	42
200	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. <i>Arthritis Research and Therapy</i> , 2011, 13, R159.	3.5	26
201	Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. <i>Lupus</i> , 2011, 20, 250-255.	1.6	96
202	Cardiovascular risk factors in inflammatory arthritis. <i>Current Opinion in Lipidology</i> , 2011, 22, 296-301.	2.7	19
203	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 54-59.	0.9	86
204	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. <i>Pharmacogenomics</i> , 2011, 12, 815-826.	1.3	69
205	Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2011, 63, 945-952.	3.4	30
206	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1068-1072.	3.4	34
207	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.9	68
208	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1641-1644.	0.9	103
209	Efficiency in follow-up immunology testing for patients with connective tissue diseases and vasculitis. <i>Clinical Medicine</i> , 2011, 11, 632-633.	1.9	1
210	SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 961-967.	0.9	45
211	Systemic lupus erythematosus: a pragmatic guide to current management: IP63. Assessment and Management of Systemic Lupus Erythematosus in the Routine Clinic Setting. <i>Rheumatology</i> , 2011, 50, iii16-iii16.	1.9	0
212	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 2011, 50, 982-988.	1.9	155
213	Systemic lupus erythematosus, regulatory T cells and pregnancy. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 635-648.	3.0	15
214	Clinical features of psoriatic arthritis. , 2011, , 1183-1193.e2.		1
215	Re-evaluation of biologic therapies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2010, 22, 273-277.	4.3	21
216	Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 881-887.	3.4	153

#	ARTICLE	IF	CITATIONS
217	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	27.8	737
218	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010, 42, 996-999.	21.4	334
219	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	1.9	111
220	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2273-2279.	2.0	54
221	Risk factors for coronary heart disease in connective tissue diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 145-153.	2.7	13
222	Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. <i>Lupus</i> , 2010, 19, 231-238.	1.6	17
223	Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 529-535.	0.9	240
224	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2199-2203.	0.9	36
225	Clinical trials in lupus: what have we learned so far?. <i>Rheumatology</i> , 2010, 49, 1025-1027.	1.9	17
226	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	2.0	83
227	The Metabolic Syndrome in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 81-97.	1.9	31
228	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2074-2082.	0.9	578
229	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	1.9	35
230	Cardiovascular Outcomes in Systemic Lupus Erythematosus: Big Studies for Big Questions. <i>Journal of Rheumatology</i> , 2009, 36, 467-469.	2.0	8
231	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
232	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	2.0	36
233	Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. <i>BMC Research Notes</i> , 2009, 2, 83.	1.4	32
234	Vitamin D in systemic lupus erythematosus: potential beyond bone health. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 297-309.	0.3	2

#	ARTICLE	IF	CITATIONS
235	The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis and Rheumatism, 2008, 58, 985-989.	6.7	56
236	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis and Rheumatism, 2008, 58, 1784-1788.	6.7	66
237	Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. Arthritis and Rheumatism, 2008, 58, 1789-1795.	6.7	15
238	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis and Rheumatism, 2008, 58, 3705-3709.	6.7	122
239	BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Annals of the Rheumatic Diseases, 2008, 67, 873-876.	0.9	49
240	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genetics, 2008, 4, e1000041.	3.5	572
241	Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Current Opinion in Lipidology, 2008, 19, 338-343.	2.7	34
242	High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus, 2007, 16, 387-393.	1.6	62
243	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Annals of the Rheumatic Diseases, 2007, 67, 672-676.	0.9	149
244	HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Annals of the Rheumatic Diseases, 2007, 66, 807-811.	0.9	64
245	Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus, 2007, 16, 731-735.	1.6	85
246	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Annals of the Rheumatic Diseases, 2007, 67, 677-682.	0.9	92
247	Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis and Rheumatism, 2007, 56, 265-273.	6.7	262
248	Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 57, 972-979.	6.7	252
249	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 4113-4119.	6.7	96
250	Improved wrist pannus volume measurement from contrast-enhanced MRI in rheumatoid arthritis using shuffle transform. Magnetic Resonance Imaging, 2007, 25, 110-116.	1.8	8
251	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	21.4	1,298
252	Rheumatoid arthritis association at 6q23. Nature Genetics, 2007, 39, 1431-1433.	21.4	361



#	ARTICLE	IF	CITATIONS
253	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <i>Nature</i> , 2007, 447, 661-678.	27.8	8,895
254	Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. <i>Nature</i> , 2007, 450, 887-892.	27.8	493
255	Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 187-195.	1.5	109
256	Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R81.	3.5	31
257	The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. <i>Arthritis and Rheumatism</i> , 2006, 54, 2963-2969.	6.7	101
258	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006, 54, 3300-3305.	6.7	93
259	Systemic lupus erythematosus, eosinophilic vasculitis and acalculous cholecystitis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 792-795.	0.7	18
260	Investigation of association of the DLG5 gene with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 273-274.	0.9	2
261	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1390-1393.	0.9	20
262	Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 50-6.	2.0	89
263	Therapy Insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 423-430.	3.3	55
264	Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 823-838.	3.3	56
265	Drug efflux transporters in rheumatoid arthritis: Comment on the article by Kremer. <i>Arthritis and Rheumatism</i> , 2005, 52, 670-670.	6.7	10
266	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005, 52, 1694-1699.	6.7	266
267	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3596-3602.	6.7	65
268	Atherogenesis and autoimmune disease: the model of lupus. <i>Lupus</i> , 2005, 14, 687-690.	1.6	43
269	“Not only” but also “and”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 1492-1502.	1.9	244
270	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005, 32, 1467-72.	2.0	87

#	ARTICLE	IF	CITATIONS
271	Coronary heart disease (CHD) in lupus: round up the usual suspects?. <i>Lupus</i> , 2004, 13, 557-560.	1.6	3
272	Systemic Lupus Erythematosus. <i>Circulation</i> , 2004, 110, 399-404.	1.6	242
273	Subclinical atherosclerosis in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2004, 31, 841-3.	2.0	10
274	Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003, 48, 3159-3167.	6.7	327
275	Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 15-19.	0.9	40
276	Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19-associated Chronic Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 2003, 36, e100-e106.	5.8	65
277	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003, 30, 288-91.	2.0	30
278	Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 1007-1011.	0.9	78
279	Genetic epidemiology: systemic lupus erythematosus. <i>Arthritis Research</i> , 2001, 3, 331.	2.0	20
280	Hyperuricemia in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 6-9.	0.9	44
281	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	56
282	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 19-23.	4.7	34
283	Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 870-874.	0.9	36
284	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 257-278.	1.9	154
285	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	3
286	Factors associated with fatigue in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 379-381.	0.9	99
287	Psoriatic Arthritis. <i>BioDrugs</i> , 1998, 9, 271-278.	4.6	15
288	An audit of ANCA in routine clinical practice. <i>Postgraduate Medical Journal</i> , 1995, 71, 605-612.	1.8	22

#	ARTICLE	IF	CITATIONS
289	The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. European Journal of Clinical Investigation, 1994, 24, 759-765.	3.4	62
290	292.â€fCharacterizing Pregnancy Vascular Changes in SLE. Rheumatology, 0, , .	1.9	0
291	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0
292	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology, 0, , .	1.9	2